Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer (PEACE)

Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)

Patients with non-resectable pancreatic cancer have a poor prognosis.The analysis of prognostic factors before treatment may be helpful in selecting appropriate candidates for chemotherapy and determining treatment strategies.

The aim of the PEACE study is to assess the vascularity of pancreatic malignant tumors using contrast-enhanced endoscopic ultrasonography and to clarify the prognostic value of tumor vascularity in patients with locally advanced and metastatic pancreatic cancer.

Study Overview

• Status: Not yet recruiting
• Conditions: Pancreas Cancer
• Intervention / Treatment: Diagnostic test: Endoscopic ultrasound (including fine needle aspiration); Other: Contrast-enhanced endoscopic ultrasound (CE-EUS); Other: Endoscopic ultrasound elastography (EG-EUS); Diagnostic test: Contrast-enhanced computed tomography (CT)

Detailed Description

Introduction and rationale:

Pancreatic cancer (PC) is one of the most lethal and therapeutically resistant malignancies, with a grim prognosis that is attributed to the late clinical presentation and the relative chemoresistance of the disease.

Even with identical chemotherapy regimens, some patients experience improvements in survival and tumor response, whereas other patients only experience inconvenience and increased toxicity. It has been suggested that the burden of treatment should not be added to the suffering of those with advanced pancreatic cancer. Therefore, understanding prognostic factors before treating patients with antitumoral agents may be helpful in selecting those patients predicted to have an improved survival and tumor response after treatment.

Studies have shown that angiogenesis is an important factor that influences the prognostic of solid tumors, including pancreatic tumors. Contrast-enhanced imaging methods can offer detailed information on tumor vascularity. Contrast-enhanced endoscopic ultrasound (CE-EUS) is a new method which allows detailed characterization of focal pancreatic masses. CE-EUS offers high-resolution images of the pancreas that far surpass those achieved by computed tomography, ultrasound, or magnetic resonance imaging. CE-EUS can detect intratumoral vessels in the pancreatic lesions. One of the fluoro-gas-containing contrast agents used in CE-EUS is Sonovue®, which is isotonic, stable and resistant to pressure, with a viscosity similar to blood. It does not diffuse into the extravascular compartment remaining within the blood vessels until the gas dissolves and is eliminated in the expired air (blood pool contrast agent). The safety profile of SonoVue showed a very low incidence of side effects; it is not nephrotoxic and the incidence of severe hypersensitivity is similar to other magnetic resonance imaging contrast agents. Moreover, Sono-Vue is approved for clinical use in European Union countries.

The hypothesis that tumors with intratumoral vessels are chemosensitive appears to be reasonable because drugs penetrate tumors through vessels. Therefore, it is possible that hypoxic condition in tumor tissue leads to chemoresistance and poor prognosis in patients with pancreatic carcinoma who received systemic chemotherapy. However, whether low vascularized tumors correlate with the chemoresistance and poor prognosis is still unclear. Patients with non-resectable pancreatic cancer have an especially poor prognosis and have many severe symptoms.The analysis of prognostic factors before treatment may be helpful in selecting appropriate candidates for chemotherapy and determining treatment strategies. For example, patients who have a poor prognosis may be treated best with only supportive care because of their short survival. Consequently, the aim of the PEACE study is to assess the vascularity of pancreatic malignant tumors with CE-EUS and to clarify the prognostic value of tumor vascularity in patients with advanced PC.

Moreover, studies have shown that angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. Chauchan et al. demonstrated that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production. Consequently, losartan reduces solid stress in tumors resulting in increased vascular perfusion. Through this physical mechanism, it can improve drug and oxygen delivery to tumors, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Accordingly, another aim of our study will be to examine the correlation between tumor vascularity and angiotensin inhibitors use in patients using these drugs to control arterial hypertension.

Objectives:

Primary Objective:

• to register time-intensity curve (TIC) analysis-derived parameters, obtained from post-processing of CE-EUS recordings with a commercially available software, before and after chemotherapy and to describe tumor changes in vascularity after treatment.

Secondary Objectives:

• to prospectively determine whether the CE-EUS parameters can be used to predict response to treatment in patients with locally advanced and metastatic pancreatic cancer. Tumor response will be assessed by contrast-enhanced computed tomography, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
• to determine the correlation between CE-EUS parameters before treatment and overall survival and progression-free survival
• to determine the correlation between changes in tumor vascularity and progression-free survival and overall survival
• to assess quantitative elastography parameters during EUS, before and after systemic treatment and determine their correlation with overall survival and progression-free survival
• to examine the correlation between tumor vascularity and angiotensin inhibitors use.

Study design:

This is a prospective, non-randomized, single-arm, observational, multicenter study aiming to assess changes in tumor vascularity using CE-EUS before and after systemic treatment in patients with locally advanced and metastatic pancreatic cancer and to examine the correlation between vascular changes and treatment response, progression-free survival and overall survival.

All patients with a suspicion of pancreatic masses will undergo EUS (including endoscopic ultrasound-fine needle aspiration for confirmation of diagnosis), with sequential elastography EUS (EG-EUS) and CE-EUS. A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-fine needle aspiration will be further verified during a clinical follow-up of at least 6 months. Contrast-enhanced computed tomography (CT) will be performed as pretreatment staging study to assess the diagnosis of pancreatic cancer, local extension of the tumor, and presence of distant and lymph node metastasis.

Patients with a confirmed diagnosis of pancreatic cancer (both adenocarcinomas and neuroendocrine tumors will be included) will undergo systemic treatment. Selection of the specific treatment regimen will be according to individual physicians' choice.

Two months after the first course of systemic chemotherapy, CT and EUS (with sequential EG-EUS and CE-EUS) will be repeated. CT will be performed in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).

CE-EUS will be performed during usual EUS examinations, with the whole movie (T0-T120s) recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis. In order to minimize human bias, all post-processing and computer analysis of digital movies will be performed within the coordinating IT Center, with all programmers and statisticians being blinded to the clinical, imaging and pathological data. Off-line analysis of time-intensity curves will be performed using Vue-Box, which yields the following quantitative parameters: Peak Enhancement (PE), Wash-in Area Under the Curve (Wi-AUC), Rise Time (RT), mean Transit Time (mTT), Time To Peak (TTP), Wash-in Rate (WiR) and Wash-in Perfusion Index (WiPI). The software also provides referenced values (expressed in percentages), aligning the set of values for the tumor Region of interest (ROI) to the parenchymal ones.

EUS-EG will also be performed during usual EUS examinations, with two movies of 10 seconds recorded on the embedded Hard Disk Drive (HDD) in order to minimize variability and to increase repeatability of acquisition. Strain Ratio (SR) and SH (Strain Histogram) will be measured; with three measurements made and recorded on the embedded HDD.

The patients will be followed-up for at least six months through clinical examination, biological exams and transabdominal ultrasound, eventually with a repeat spiral CT / EUS after six months.

For each patient, the following information will be recorded and uploaded to http://oncobase.umfcv.ro/ (this website aims to provide hosting and support for multicentric studies; all registered users can access the project and submit the data or upload files through a form defined and controlled by the project's coordinator):

• Age
• Gender
• Primary tumor location (pancreatic head or pancreatic body and tail)
• Primary tumor size
• Tumor status (metastatic or locally advanced)
• Site of metastasis
• Histologic grade
• Serum carcinoembryonic antigen (CEA) level
• Serum carbohydrate antigen 19-9 (CA19-9) level
• Prior biliary drainage (presence or absence).
• Antitumoral agent (chemotherapy regimen).
• Angiotensin inhibitors (drug, dose).
• Parameters of the pancreatic cancer CT reporting template
• EUS, CE-EUS, EG-EUS parameters (echogenicity, echostructure, size, presence/absence of power Doppler signals, Strain Ratio, Strain Histogram, Peak Enhancement (PE), Wash-in Area Under the Curve (Wi-AUC), Rise Time (RT), mean Transit Time (mTT), Time To Peak (TTP), Wash-in Rate (WiR) and Wash-in Perfusion Index (WiPI)).

• Study Type: Observational
• Enrollment (Anticipated): 200

Contacts and Locations

• Study Contact: Name: Adrian Saftoiu, MD PhD FASGE; Phone Number: +40 744 823355; Email: adriansaftoiu@gmail.com
• Study Contact Backup: Name: Irina Cazacu, MD; Phone Number: +40 785 216 587; Email: irina.cazacu89@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 88 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with a confirmed diagnosis of locally advanced/metastatic pancreatic cancer (both adenocarcinoma and neuroendocrine tumors will be included)

Description

Inclusion Criteria:

• Age 18 to 90 years old, men or women
• Signed informed consent for CE-EUS, EG-EUS and FNA biopsy
• The diagnosis of pancreatic cancer histologically confirmed by fine needle aspiration (FNA) with EUS
• Both pancreatic adenocarcinoma and pancreatic neuroendocrine tumors will be included
• Unresectable, locally advanced and/or metastatic disease.

Exclusion Criteria:

• Previous chemotherapy or radiotherapy
• Resectable pancreatic tumors

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Non-resectable pancreatic cancer; All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months. Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included. Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment

Diagnostic test: Endoscopic ultrasound (including fine needle aspiration); EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.; Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.; Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.; EUS-FNA will be performed in all pancreatic masses with at least four passes.; Other: Contrast-enhanced endoscopic ultrasound (CE-EUS); CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.; The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).; The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.; All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box; Other: Endoscopic ultrasound elastography (EG-EUS); EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD; The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided; The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.; SR and SH will be measured; with three measurements made and recorded on the embedded HDD.; Diagnostic test: Contrast-enhanced computed tomography (CT); Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.; A template will be used to report the imaging results.; The template includes morphologic, arterial, venous, and extrapancreatic evaluations.; Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of Peak Enhancement (PE) from baseline to 2 months after the first course of treatment	PE represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment
Change of Wash-in Area Under the Curve (Wi-AUC) from baseline to 2 months after the first course of treatment	Wi-AUC represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment
change of Rise Time (RT) from baseline to 2 months after the first course of treatment	RT represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment
change of mean Transit Time (mTT) from baseline to 2 months after the first course of treatment	mTT represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment
Change of Time To Peak (TTP) from baseline to 2 months after the first course of treatment	TTP represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment
Change of Wash-in Rate (WiR) from baseline to 2 months after the first course of treatment	Wir represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment
Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment	WiPI represents a TIC analysis-derived parameter, obtained from post-processing of CE-EUS recordings with a commercially available software	baseline and 2 months after the first course of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	The overall survival (OS) will be measured from the first day of chemotherapy to the date of death	1 year
Progression-free survival	The progression-free survival (PFS) will be measured from the first day of chemotherapy to the date of progressive disease.	1 year
Tumor response to treatment	Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST). According to RECIST guidelines,complete response (CR) is defined as the complete disappearance of the tumor, partial response (PR) as ≥30% decrease in longest diameter (LD), progressive disease (PD) as ≥20% increase in LD, and stable disease (SD) as a decrease or increase less than PR or PD based on anatomic assessment. Patients with CR or PR will be defined as responders, whereas those with PD or SD are defined as non-responders.	2 months after the first course of treatment

Collaborators and Investigators

• Sponsor: University of Medicine and Pharmacy Craiova
• Collaborators: M.D. Anderson Cancer Center; University College London Hospitals; Asan Medical Center; Singapore General Hospital; Copenhagen University Hospital at Herlev; Iuliu Hatieganu University of Medicine and Pharmacy; Shengjing Hospital; Newcastle-upon-Tyne Hospitals NHS Trust; Institut Paoli-Calmettes; Ospedale San Raffaele; University of Santiago de Compostela; Tokyo Medical University; Caritas-Krankenhaus Bad Mergentheim; Central Military Hospital Bucharest; Ponderas Regina Maria Hospital Bucharest; Helios Kliniken Meiningen; Hospital Märkisch Oderland Wriezen/ Strausberg
• Investigators: Principal Investigator: Adrian Saftoiu, MD PhD FASGE, University of Medicine and Pharmacy Craiova

Publications and helpful links

General Publications

• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4-6. doi: 10.1093/jnci/82.1.4. No abstract available.
• Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209. doi: 10.1016/j.bpg.2005.10.001.
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994 Oct 21;79(2):185-8. doi: 10.1016/0092-8674(94)90187-2. No abstract available.
• Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999 Mar;79(9-10):1553-63. doi: 10.1038/sj.bjc.6690248.
• Saftoiu A, Vilmann P, Bhutani MS. The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. Endosc Ultrasound. 2016 Nov-Dec;5(6):368-372. doi: 10.4103/2303-9027.190932.
• Yamashita Y, Ueda K, Itonaga M, Yoshida T, Maeda H, Maekita T, Iguchi M, Tamai H, Ichinose M, Kato J. Tumor vessel depiction with contrast-enhanced endoscopic ultrasonography predicts efficacy of chemotherapy in pancreatic cancer. Pancreas. 2013 Aug;42(6):990-5. doi: 10.1097/MPA.0b013e31827fe94c.
• Sanchez MV, Varadarajulu S, Napoleon B. EUS contrast agents: what is available, how do they work, and are they effective? Gastrointest Endosc. 2009 Feb;69(2 Suppl):S71-7. doi: 10.1016/j.gie.2008.12.004. No abstract available.
• Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res. 2005 Aug 1;11(15):5622-30. doi: 10.1158/1078-0432.CCR-05-0459.
• Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, Popovic Z, Huang P, Bawendi MG, Boucher Y, Jain RK. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516. doi: 10.1038/ncomms3516.

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2018
• Primary Completion (Anticipated): February 1, 2023
• Study Completion (Anticipated): February 1, 2023

Study Registration Dates

• First Submitted: February 13, 2018
• First Submitted That Met QC Criteria: April 29, 2018
• First Posted (Actual): May 1, 2018

Study Record Updates

• Last Update Posted (Actual): May 1, 2018
• Last Update Submitted That Met QC Criteria: April 29, 2018
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Keywords: prognostic; contrast-enhanced endoscopic ultrasound; endoscopic ultrasound elastography; tumor vascularity
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: PEACE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No